Fundraising Fox

Osmol Therapeutics

New Haven, US · Founded 2016 · Delaware corporation · 6 employees on LinkedIn

Find your way into Osmol Therapeutics

24 people in our graph share verified history with the Osmol Therapeutics team — schools, employers, funds. One of them is your warm intro.

Teresa Bitettiunlockedknows Bob Linke · together at Osmol Therapeutics (overlapped)
×8knows the team · via Albion College
×3knows the team · via Rapid Micro Biosystems

Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.

BiotechHealthtech

Founders & leadership

BD
Brian DixonExecutive
BLBob Linke
Bob LinkeinPresident & CEOBob Linke is President and CEO of Osmol Therapeutics, a preclinical biotech company developing a therapeutic to prevent chemotherapy-induced neuronal damage. He has held CEO positions in biopharmaceutical companies, raising capital for development programs, and brings prior experience from large pharmaceutical organizations.
RW
Ron WeitzmanChief Medical Officer

Board

BE
Barbara EhrlichChief Scientific Advisor

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 2 rounds · 2016–2022

▶$2.3MraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Michael EhrlichDirector
  • Robert BermanDirector
  • Robert LinkeExecutive Officer, Director
  • Vlad CoricDirector
Offering amount
$7.5M
Amount sold
$2.3M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$550KraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian DixonExecutive Officer, Director
Offering amount
$3M
Amount sold
$550K
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
OS Therapies5 shared keywordsOS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.
Applied Therapeutics5 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.

Companies competing with Osmol Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Osmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023businesswire.com · Dec 2022Osmol Therapeutics Closes First $5.2M Tranche of $7.5M Series A-1 Fundingfinsmes.com · Apr 2022Osmol Therapeutics lands $5.2M to develop neuropathy treatmenthartfordbusiness.com · Apr 2022

Frequently asked questions

What does Osmol Therapeutics do?
Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.
How much funding has Osmol Therapeutics raised?
Osmol Therapeutics has disclosed $2.9M raised across 2 rounds.
Where is Osmol Therapeutics headquartered?
Osmol Therapeutics is headquartered in New Haven, US.